Chinanews client, Beijing, November 12th (Reporter Zhang Ni) Recently, the launch of the national procurement of high-value medical consumables has attracted great attention.
The price of coronary stents has dropped by over 90%, making many patients applaud.
At the same time, at present, all localities are actively forming a purchasing alliance to "hold group and bargain."
After the government's "soul bargaining" becomes normal, how much money can ordinary people save in future medical treatment?
Data map: The doctor performs surgery on the patient (the picture is not relevant) Xinhua Hospital
Many places open the "group buying" mode of high-value medical consumables
The average price dropped from 13,000 yuan to 700 yuan. Recently, the first batch of national centralized procurement of coronary stents has set a "floor price". Compared with 2019, the average price of the same products of the same company has been reduced by 93%.
The opening of the “national procurement” of high-value medical consumables has aroused widespread concern. After all, it is time to come!
According to the previous introduction of the National Medical Insurance Bureau, 2,408 medical institutions participated in this centralized procurement, and the intended purchase volume reached 1.07 million in the first year.
It is expected that patients across the country will use the selected products after the national centralized procurement price reduction in January 2021.
In fact, in addition to the substantial price cuts of heart stents, local levels have begun to actively "group procurement" for high-value consumables, and the prices of some high-value medical consumables have dropped by more than 50% on average.
It confirms the voice of the industry before-high-value consumables "4+7" will only be late, but will not be absent.
For example, in Jiangsu, Jiangsu has previously established the Provincial Sunshine Purchasing Alliance composed of 157 three-level public medical institutions in the whole province, and has successively carried out three rounds of group alliance centralized procurement.
The above-mentioned purchases involved 6 categories and thousands of specifications, including heart stents, coronary balloons, and primary replacement artificial knee joints. The average drop was over 50%, and the highest drop was 86.4%.
Hainan also played a combined punch to promote centralized procurement of medical consumables.
In addition to participating in the national organization of centralized procurement of coronary stents, the province also organized the procurement of intra-provincial alliance consumables such as intraocular lenses, coronary balloons and new crown testing reagents.
Take intraocular lenses as an example. At the end of last year, Hainan Province participated in the inter-provincial alliance of public medical institutions' cross-regional joint procurement of intraocular lenses. Compared with the original purchase price, the proposed price dropped by 85%, and the average drop was 44%.
In addition, earlier, the medical security bureaus of the Beijing-Tianjin-Hebei region also signed the "Beijing-Tianjin-Hebei Centralized Procurement of Medicines and Medical Consumables Cooperation Framework Agreement", aiming to promote the centralized procurement of medicines and medical consumables in Beijing-Tianjin-Hebei.
It can be seen that active group procurement will become a normal operation.
Data map: A patient uses the face recognition system to make an appointment with an expert number under guidance.
Photo by Wang Guangzhao
Take the account! How much money can "group buying" save the people?
Inflated prices of medicines and medical consumables have always been one of the crux of the common people's high medical care.
From medicines to consumables, the core goal of volume procurement is to squeeze out the price "moisture" so that patients can use medicines and medical consumables at a relatively low price.
So, how much money did the “quantity-for-price” national centralized procurement save?
Numbers can be expressed most intuitively.
For example, starting this month, the third batch of countries have organized the implementation of centralized drug procurement.
According to Zhong Dongbo, Director of the Department of Pharmaceutical Prices and Bidding and Purchasing of the National Medical Insurance Administration, according to static calculations, the three batches of medicines can save about 53.9 billion yuan nationwide.
Calculating on the basis of 40% paid by ordinary people, it can save about 21.6 billion yuan.
At the same time, medical insurance saves money, and by expanding the medical insurance reimbursement drug catalog and improving the reimbursement level, the common people can get more benefits.
Previously, in addition to medicines, all parties have been calling for the return of high-value medical consumables to reasonable prices.
Taking this centralized collection of coronary stents as an example, data shows that the interventional treatment of coronary heart disease in China has developed rapidly. From 2009 to 2019, the number of cases has grown from 230,000 to more than 1 million, with an annual growth rate of 10%- 20%.
At present, the price of coronary stents used by medical institutions ranges from several thousand yuan to several tens of thousands yuan, and the burden on patients is heavy.
In this centralized procurement, the intended purchase volume reached 1.07 million in the first year.
Calculated based on the intended purchase volume, it is estimated that 10.9 billion yuan will be saved.
From a local perspective, the "alliance bargaining" between various regions has also seen tangible results.
For example, Hainan’s participation in the cross-regional joint procurement of intraocular lenses is expected to save Hainan Province’s medical insurance fund 25 million yuan.
The centralized procurement of the group alliance launched by Jiangsu is expected to save about 1.5 billion yuan.
Data map: Photographed by China News Agency reporter Yang Di in the outpatient hall of a hospital
Say goodbye to "consuming doctors", can doctors increase their sunshine income?
Data show that the market size of China's medical consumables is 320 billion yuan, of which 150 billion yuan is high-value medical consumables.
Behind the huge market size is the existence of "consumption of medical care" in public medical institutions all year round.
This centralized procurement is an important step in the reform of high-value consumables. The industry generally believes that in the future, the management of high-value consumables will be comprehensive.
In fact, as early as July 2019, the General Office of the State Council issued the "Reform Plan for Governing High-Value Medical Consumables."
The document emphasizes that “straighten out the price system for high-value medical consumables, improve the whole-process supervision and management of high-value medical consumables, purify the market environment of high-value medical consumables and the medical service practice environment, and support domestic high-value medical consumables with independent intellectual property rights to enhance core competitiveness "This means that the country must conduct comprehensive governance in terms of prices, supervision, markets, and services.
In addition, it is worth mentioning that the above plan has clearly proposed "abolish the medical consumables bonus of public medical institutions", and achieve "zero markup" sales of medical consumables in all public medical institutions by the end of 2019.
On September 1st of the same year, the "Administrative Measures for Medical Consumables in Medical Institutions (Trial)" jointly issued by the National Health Commission and the State Administration of Traditional Chinese Medicine was also officially implemented.
In terms of procurement, the "Measures" particularly emphasizes that the procurement of medical consumables shall be managed in a unified manner. Medical institutions above the second level should designate specific departments as medical consumables management departments. Other departments or departments shall not engage in procurement activities.
The implementation of high-value consumables for mass procurement, coupled with the introduction of DRG (diagnostic-related groupings) paid for, supply chain profits will inevitably become thinner and thinner, and the gray interest chain between enterprises and medical institutions will also be cut.
However, the implementation of centralized procurement is bound to move the "cheese" of some people.
How to mobilize the enthusiasm of medical staff to participate in the reform of managing high-value medical consumables is very important.
In fact, the solution to this problem is involved in the "Reform Plan for Governing High-Value Medical Consumables".
The document proposes to speed up the establishment of a remuneration system that meets the characteristics of the industry.
Implement the requirements of “allowing medical and health institutions to break through the current wage control level of public institutions, allowing medical service income to deduct costs and withdrawing various funds as required to be used for personnel rewards”, and improve the salary distribution policy.
In the "Administrative Measures for Medical Consumables in Medical Institutions (Trial)", it is also clear that the purchase of medical consumables shall not be used as the basis for the economic allocation of departments and personnel, and that improper economic benefits shall not be sought in the purchase of medical consumables.
In the opinion of experts in the industry, a series of reforms will also promote the transformation of the hospital's development model, changing the current extensive model of reliance on medicines and consumption of remedies, thereby enhancing the hospital’s refined management capabilities and changing the hospital’s economic power and operation mode.
In addition, some voices believe that in the subsequent reform of the medical system, not only the high-value medical consumables or drug price system must be straightened out, but also the value of intermediate services in the medical system.
While reducing the price of consumables or medicines, the value of knowledge and the labor value of medical staff should be more reflected.
(Finish)